Impact of metabolic dysfunction-associated steatotic liver disease on liver metastasis and survival in pancreatic cancer

doi:10.3748/wjg.v32.i11.115488

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 11

This Article

(34)

(46)

(0)

(1)

(672)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Mar 21, 2026; 32(11): 115488
Published online Mar 21, 2026. doi: 10.3748/wjg.v32.i11.115488

Table 1 Baseline characteristics of the participants (n = 2123), n (%)

Characteristics	Total (n = 2123)	With liver metastasis (n = 540)	Without liver metastasis (n = 1584)	P value
Patient
Age (years), median IQR	66 (58-73)	65 (58.0-72.0)	66 (58.0-73.0)	0.057
Male	1118 (52.6)	298 (55.2)	820 (51.8)	0.174
Body mass index (kg/m²), median IQR	22.7 (20.8-24.9)	22.8 (20.7-25.1)	22.7 (20.8-24.8)	0.571
Diabetes mellitus	1042 (49.1)	245 (45.4)	797 (50.3)	0.046
Hypertension	919 (43.3)	239 (44.3)	680 (43.0)	0.598
Cirrhosis	4 (0.2)	1 (0.2)	3 (0.2)	0.984
HSI, median IQR	33.9 (30.6-37.5)	34.0 (30.7-37.8)	33.8 (30.6-37.4)	0.585
HSI > 30	1683 (79.3)	426 (78.9)	1257 (79.4)	0.798
HSI > 36	729 (34.3)	192 (35.6)	537 (33.9)	0.490
TG (mg/dL), median IQR	102 (75-138)	100 (79-143)	103 (75-136)	0.929
HDL (mg/dL), median IQR	42 (32-50)	40 (32-47)	42 (32-52)	0.043
LDL (mg/dL), median IQR	86 (64-116)	84 (62-105)	87 (65-118)	0.334
Total bilirubin (mg/dL), median IQR	0.7 (0.5-1.4)	0.7 (0.5-1.3)	0.7 (0.5-1.4)	0.461
Tumor
Location				< 0.001
Head	904 (42.6)	181 (33.5)	723 (45.7)
Body	474 (22.3)	114 (21.1)	360 (22.8)
Tail	375 (17.7)	139 (25.7)	236 (14.9)
Mixed	369 (17.4)	106 (19.7)	263 (16.6)
Size (mm), median IQR	36.0 (28.0-48.0)	41 (32-55)	35 (26-45)	< 0.001
CA19-9 (U/mL), median IQR	259.6 (31.4-1647.0)	975.0 (45.0-6092.3)	206.2 (30.0-1046.3)	< 0.001

IQR: Interquartile range; HSI: Hepatic steatosis index; TG: Triglyceride; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CA: Carbohydrate antigen.

Full Size Table

Citation: Chon HY, Rhee H, Kim J, Leem G, Jo JH, Chung MJ, Park JY, Bang S, Park SW, Kim SU, Lee HS. Impact of metabolic dysfunction-associated steatotic liver disease on liver metastasis and survival in pancreatic cancer. World J Gastroenterol 2026; 32(11): 115488
URL: https://www.wjgnet.com/1007-9327/full/v32/i11/115488.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i11.115488

Chon HY, Rhee H, Kim J, Leem G, Jo JH, Chung MJ, Park JY, Bang S, Park SW, Kim SU, Lee HS. Impact of metabolic dysfunction-associated steatotic liver disease on liver metastasis and survival in pancreatic cancer. World J Gastroenterol 2026; 32(11): 115488 [DOI: 10.3748/wjg.v32.i11.115488]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.